The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis

UGT1A1 Gene Polymorphisms and the Toxicities of FOLFIRI in Chinese Han Patients with Gastrointestinal Cancer

(2013) Chen-fei Zhou et al.   Anti-Cancer Agents in Medicinal Chemistry

Examining the stability of genetic risk effect as evidence accumulates in the context of meta-analysis

(2013) Elias Zintzaras   COMPUTERS IN BIOLOGY AND MEDICINE

UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients

(2013) Jing Gao et al.   MEDICAL ONCOLOGY

Polymorphisms of the UDP-Glucuronosyl Transferase 1A Genes Are Associated with Adverse Events in Cancer Patients Receiving Irinotecan-Based Chemotherapy

(2013) Kazuyuki Inoue et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer

(2012) J-C Jo et al.   BRITISH JOURNAL OF CANCER

A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of theUGT1A1andCYP2A6Polymorphisms on Clinical Activity

(2012) Yoon Hee Choi et al.   ONCOLOGY

UGT1A1predicts outcome in colorectal cancer treated with irinotecan and fluorouracil

(2012) Yan Wang   WORLD JOURNAL OF GASTROENTEROLOGY

Examination of Factors Affecting Adverse Reactions and Dosage Reduction in UGT1A1 Genotyped Patients: A Retrospective Survey of Irinotecan

(2012) Keinosuke Okazaki et al.   YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms

(2011) Taroh Satoh et al.   CANCER SCIENCE

Prospective Phase II Study of FOLFIRI for mCRC in Japan, Including the Analysis of UGT1A1*28/*6 Polymorphisms

(2011) Y. Okuyama et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer

(2010) Yu Sunakawa et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk

(2010) Z.-Y. Hu et al.   CLINICAL CANCER RESEARCH

The UGT1A1*28 Genotype and the Toxicity of Low-Dose Irinotecan in Patients With Advanced Lung Cancer

(2010) Tomohide Sugiyama et al.   ONCOLOGY RESEARCH

Irinotecan pharmacogenomics

(2010) Sharon Marsh et al.   PHARMACOGENOMICS

Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on theUGT1A1*28polymorphism

(2009) Shoichi Hazama et al.   CANCER SCIENCE

UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients

(2009) Masahide Onoue et al.   International Journal of Clinical Oncology

Clinical Significance of UDP-Glucuronosyltransferase 1A1*6 for Toxicities of Combination Chemotherapy with Irinotecan and Cisplatin in Gynecologic Cancers

(2009) Masashi Takano et al.   ONCOLOGY

Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy

(2008) Y. Akiyama et al.   ANNALS OF ONCOLOGY

Phase I/II Pharmacokinetic and Pharmacogenomic Study of UGT1A1 Polymorphism in Elderly Patients With Advanced Non–Small Cell Lung Cancer Treated With Irinotecan

(2008) N Yamamoto et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Synthesis of genetic association studies for pertinent gene–disease associations requires appropriate methodological and statistical approaches

(2008) Elias Zintzaras et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Importance of UDP-glucuronosyltransferase 1A1∗6 for irinotecan toxicities in Japanese cancer patients

(2007) Kimie Sai et al.   CANCER LETTERS